I didn't think that any shareholders had to opt for the CVRs - that was part of the deal if you accepted the offer from Cubist. I assume you probably sold your shares in the market prior to the offer closing for a small premium to the cash offer.
Anyway for the mighty Merck to sell just $14m of Sivextro in 2016 is pretty amazing. It just shows how much Cubist overpaid for Trius. So we were extremely lucky to get what we got! I have owned 4 biotech shares that sold out for cash plus CVRs. It looks like I'm going to get nothing from any of the CVRs. My view is that I'm a very lucky guy - the shares of all 4 were worth considerably less than the cash that I got.
News 
Market Data 
Discover 
